About this trial
To confirm the efficacy of DIMS lenses in controlling myopia progression, we planned a prospective, single-centre, randomised, double-blind, controlled, non-inferiority clinical study.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
The subjects had spherical RE of -1.00 to -6.00 D, astigmatism ≤ 1.50 D, anisometropia ≤ 1.50 D
the best corrected visual acuity in the left and right eyes subjective optometry is greater than or equal to 1.0
Disqualifiers
Candidate subjects were excluded from the study if they had strabismus, ocular limitations, or systemic abnormalities affecting vision and ocular motility
Trial design
Parallel
Treatments tested in this trial
frame lens
DeviceA randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
Treatment groups
Trial outcomes
Primary outcomes
Cycloplegic objective refraction
Cycloplegic objective refraction was measured with an autorefractor (Topcon KR8900, Japan)
Secondary outcomes
Axial Length
Axial length (AL) was measured with an AL-Scan optical biometer (Nidek, Japan)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: